NYSEAMERICAN:NBY NovaBay Pharmaceuticals (NBY) Stock Price, News & Analysis → The #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique Way (From Smallcaps Daily) (Ad) Free NBY Stock Alerts $0.08 0.00 (-3.47%) (As of 11:27 AM ET) Add Compare Share Share Today's Range$0.08▼$0.0950-Day Range N/A52-Week Range$0.07▼$1.28Volume801,751 shsAverage Volume3.30 million shsMarket Capitalization$351,535.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort Interest Get NovaBay Pharmaceuticals alerts: Email Address Ad Unstoppable ProsperityRSVP: Charles Payne’s Cash Flow WorkshopAre you ready to find untapped value in the stocks you already own… Without selling a single share… Then you need to know these Cash Flow Trade Strategies.Register For Free Now! About NovaBay Pharmaceuticals Stock (NYSEAMERICAN:NBY)NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through traditional and digital beauty retailers and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.Read More NBY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NBY Stock News HeadlinesMay 4, 2024 | americanbankingnews.comNovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Share Price Crosses Above 50-Day Moving Average of $0.00April 17, 2024 | finance.yahoo.comNovaBay Pharmaceuticals Reports Preliminary Eyecare and Wound Care Revenue Increased 13% for the First Quarter of 2024 on Lower Sales and Marketing ExpensesMay 8, 2024 | Crypto 101 Media (Ad)Elon Musk Secret Crypto Plot ExposedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.April 17, 2024 | markets.businessinsider.comBuy Rating Maintained for NovaBay Pharma Amid Strategic Refocus and Resilient Revenue PerformanceMarch 27, 2024 | finance.yahoo.comNovaBay Pharmaceuticals, Inc. (AMEX:NBY) Q4 2023 Earnings Call TranscriptMarch 27, 2024 | finance.yahoo.comQ4 2023 NovaBay Pharmaceuticals Inc Earnings CallMarch 15, 2024 | barrons.comNovaBay Pharmaceuticals Inc.March 14, 2024 | markets.businessinsider.comNovaBay Pharmaceuticals To Sell DERMAdoctor Skincare Business - Quick FactsMay 8, 2024 | Crypto 101 Media (Ad)Elon Musk Secret Crypto Plot ExposedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.March 13, 2024 | markets.businessinsider.comNovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare ProfessionalsFebruary 26, 2024 | finance.yahoo.comNovaBay Pharmaceuticals, Inc. (NBY)January 30, 2024 | finance.yahoo.comNovaBay Pharmaceuticals Reports 64% Year-Over-Year Growth in Avenova Unit Subscription-Based SalesJanuary 29, 2024 | msn.comWhy ZIM Integrated Shipping Services Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving PremarketJanuary 9, 2024 | finance.yahoo.comNovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma’s Extensive Distributor NetworkDecember 6, 2023 | finance.yahoo.comNovaBay Pharmaceuticals Partners with Woo University to Educate Eyecare Professionals on the Use of Amniotic MembranesNovember 12, 2023 | finance.yahoo.comNovaBay Pharmaceuticals, Inc. (AMEX:NBY) Q3 2023 Earnings Call TranscriptNovember 9, 2023 | benzinga.comRecap: NovaBay Pharmaceuticals Q3 EarningsNovember 9, 2023 | finance.yahoo.comNovaBay Pharmaceuticals Reports Third Quarter 2023 Financial ResultsNovember 2, 2023 | finance.yahoo.comNovaBay Pharmaceuticals to Hold Third Quarter 2023 Conference Call on November 9, 2023October 21, 2023 | thestreet.comNovaBay Pharmaceuticals: CEO InterviewOctober 11, 2023 | finance.yahoo.comNovaBay Pharmaceuticals Expands Physician Dispensed Sales Channel with New Avenova ProgramsOctober 2, 2023 | finance.yahoo.comNovaBay Pharmaceuticals to Present at the Dawson James Small Cap Growth ConferenceSeptember 11, 2023 | marketwatch.comNovaBay Pharma Shares Rise 42% After Deal With BioStem TechnologiesSeptember 11, 2023 | markets.businessinsider.comNovaBay Pharma Agrees With BioStem To Commercialize Amniotic Tissue Allograft As Avenova AllograftSeptember 11, 2023 | benzinga.comWhy NovaBay Pharmaceuticals Stock Is Blasting HigherSeptember 11, 2023 | msn.comNovaBay stock soars 86% on optic allograft product dealSeptember 11, 2023 | marketwatch.comNovaBay to Commercialize BioStem Technologies' Amniotic Tissue AllograftSee More Headlines Receive NBY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NovaBay Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/26/2024Today5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNYSEAMERICAN:NBY CUSIPN/A CIK1389545 Webnovabay.com Phone(510) 899-8800Fax510-474-1577Employees24Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($9.9465) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,610,000.00 Net Margins-79.70% Pretax Margin-79.70% Return on Equity-146.20% Return on Assets-69.63% Debt Debt-to-Equity RatioN/A Current Ratio1.85 Quick Ratio1.25 Sales & Book Value Annual Sales$14.40 million Price / Sales0.03 Cash FlowN/A Price / Cash FlowN/A Book Value$1.53 per share Price / Book0.06Miscellaneous Outstanding Shares4,210,000Free Float4,160,000Market Cap$364,165.00 OptionableNot Optionable Beta2.82 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Justin M. Hall Esq. (Age 46)President, CEO, General Counsel, Chief Compliance Officer, Corporate Secretary & Director Comp: $364.15kMr. Tommy Law (Age 39)Controller, Interim CFO & Treasurer Comp: $155.48kKey CompetitorsPolarityTENASDAQ:PTEIQAsterias BiotherapeuticsNYSEAMERICAN:AST9 Meters BiopharmaNASDAQ:NMTRHemispherx BioPharmaNYSEAMERICAN:HEBSmart for LifeNASDAQ:SMFLView All Competitors NBY Stock Analysis - Frequently Asked Questions How have NBY shares performed in 2024? NovaBay Pharmaceuticals' stock was trading at $0.1802 at the start of the year. Since then, NBY shares have decreased by 53.7% and is now trading at $0.0835. View the best growth stocks for 2024 here. Are investors shorting NovaBay Pharmaceuticals? NovaBay Pharmaceuticals saw a decrease in short interest in April. As of April 15th, there was short interest totaling 208,100 shares, a decrease of 71.0% from the March 31st total of 718,800 shares. Based on an average daily trading volume, of 3,490,000 shares, the short-interest ratio is presently 0.1 days. Currently, 0.6% of the shares of the company are sold short. View NovaBay Pharmaceuticals' Short Interest. How were NovaBay Pharmaceuticals' earnings last quarter? NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) released its quarterly earnings data on Tuesday, March, 26th. The biopharmaceutical company reported ($0.95) earnings per share for the quarter. The biopharmaceutical company earned $3.73 million during the quarter. NovaBay Pharmaceuticals had a negative trailing twelve-month return on equity of 146.20% and a negative net margin of 79.70%. When did NovaBay Pharmaceuticals' stock split? NovaBay Pharmaceuticals's stock reverse split before market open on Wednesday, November 16th 2022. The 1-35 reverse split was announced on Wednesday, November 16th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 16th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What other stocks do shareholders of NovaBay Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other NovaBay Pharmaceuticals investors own include Aeterna Zentaris (AEZS), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Bionano Genomics (BNGO), Heat Biologics (HTBX), iBio (IBIO), Matinas BioPharma (MTNB), Novan (NOVN), ADMA Biologics (ADMA) and Vaxart (VXRT). How do I buy shares of NovaBay Pharmaceuticals? Shares of NBY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEAMERICAN:NBY) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorElon Musk Secret Crypto Plot ExposedCrypto 101 MediaAI “wealth window” is closing June 25thParadigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressThe #1 lithium battery stock to have on your radar in 2024!Smallcaps Daily[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingCharles Payne Demystifies OptionsUnstoppable Prosperity Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NovaBay Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
